Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis

December 28, 2025 updated by: Laboratorios Silanes S.A. de C.V.

Efficacy and Safety Study of the Etoricoxib/Betamethasone Combination Compared With Etoricoxib for the Treatment of Patients Diagnosed With an Acute Episode of Bursitis, Tendinitis, or Synovitis of the Shoulder, Elbow, Knee, or Ankle

Phase III, multicenter, prospective, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of a fixed-dose combination of etoricoxib/betamethasone compared with etoricoxib alone in patients with an acute episode of bursitis, tendinitis, or synovitis affecting the shoulder, elbow, knee, or ankle.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is a Phase III, multicenter, prospective, randomized, double-blind, parallel-group study to compare the efficacy and safety of a fixed-dose combination of etoricoxib/betamethasone versus etoricoxib alone in patients with an acute episode of bursitis, tendinitis, or synovitis of the shoulder, elbow, knee, or ankle. Eligible participants will be randomized to receive either etoricoxib/betamethasone 90 mg/0.25 mg once daily for 14 days (Group A) or etoricoxib 90 mg once daily for 14 days (Group B). The study includes three visits (Day 1 baseline, Day 7 ± 2, Day 14 ± 2) and two follow-up calls (Day 3 ± 2 and Day 10 ± 2); investigators will collect medical history, perform physical examinations focused on the affected region, and review laboratory and diagnostic assessments as applicable. Pain intensity in the affected joint will be assessed using a Visual Analog Scale (VAS) during active movement and at rest at each visit/call, and daily by patients in a trained Patient Diary completed in the afternoon at the same time each day. Outcomes include changes from baseline in maximum pain (movement and rest) over 14 days, clinical improvement at Days 7 and 14 using the Clinical Global Impression scale, patient and investigator global assessments, and safety based on adverse events summarized by treatment group; rescue medication use (paracetamol 500 mg) and treatment adherence will also be evaluated.

Study Type

Interventional

Enrollment (Actual)

89

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Mexico
    • Mexico City
      • Mexico City, Mexico City, Mexico, 11000
        • Laboratorios Silanes, S.A. de C.V.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients willing and able to participate in the study and provide written informed consent.
  • Male or female.
  • Age ≥ 18 years at study entry.
  • Women of childbearing potential who use an acceptable contraceptive method (barrier, oral hormonal, injectable, subdermal), or women who are naturally postmenopausal or surgically sterile.
  • Clinical diagnosis of an acute episode of tendinitis, bursitis, or synovitis of the shoulder, elbow, knee, or ankle, with onset within 7 days prior to the first dose of study medication.
  • A score ≥ 40 mm on a 100-mm Visual Analog Scale (VAS) for maximum pain intensity during active movement, as reported by the patient at the time of study inclusion.
  • In the opinion of the Principal Investigator or treating physician, the participant is an appropriate candidate for treatment with the investigational product.

Exclusion Criteria:

  • Participation in another clinical study involving an investigational treatment, or participation in such a study within 4 weeks prior to study start.
  • Patients whose participation could be influenced (e.g., employment relationship with the study site or sponsor, vulnerable populations, etc.).
  • In the investigator's medical judgment, any disease that affects prognosis and prevents outpatient management, including but not limited to: terminal cancer, renal, cardiac, respiratory, or hepatic failure, mental illness, or scheduled surgical procedures or hospitalizations.
  • History or presence of any disease or condition that, in the investigator's opinion, could pose a risk to the patient or confound the efficacy and safety evaluation of the investigational product, such as significant degenerative disease or an infectious process in the joints of interest.
  • Fever: axillary temperature > 37.5°C within 2 days prior to or at the time of study inclusion.-
  • Pregnant or breastfeeding patients.
  • Contraindication to the study medications.
  • History of allergic reaction to NSAIDs (non-steroidal anti-inflammatory drugs), paracetamol (acetaminophen), or known hypersensitivity to the study medications.
  • Significant history of gastrointestinal disorders (e.g., gastric ulcer, Crohn's disease, ulcerative colitis, gastrointestinal bleeding, etc.).
  • History of congestive heart failure (NYHA Class II-IV), established ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease (including patients who have recently undergone coronary revascularization procedures or angioplasty).
  • Treatment with corticosteroids within 1 month prior to study start.
  • Treatment with NSAIDs within 48 hours prior to study start, except for cardioprotective-dose aspirin.
  • Tendinitis or bursitis secondary to a systemic inflammatory disease, or synovitis secondary to hemophilia.
  • History of harmful alcohol and/or drug use causing adverse health and social effects.
  • Clinical suspicion of joint infection or another joint disease other than tendinitis, bursitis, or synovitis.
  • History of chronic hepatic impairment (Child-Pugh A, B, and/or C).
  • History of acute renal failure or chronic kidney disease (glomerular filtration rate < 30 mL/min/1.73 m²).
  • Significant history of known coagulation disorders (e.g., von Willebrand disease, hemophilia, vitamin K deficiency, etc.) or use of anticoagulants.
  • Oncology patients (except basal cell skin cancer or patients with cancer in remission) or patients with severe diseases that, in the investigator's opinion, have a poor prognosis or a life expectancy of less than 1 year, as well as mental illnesses.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Etoricoxib + Betamethasone
Administered orally, 1 tablet a day for 14 days.
Drug: Fixed Dose Etoricoxib + Betamethasone
One tablet of 90 mg / 0.25 mg a day, for 14 days
Active Comparator: Etoricoxib
Administered orally, 1 tablet a day for 14 days.
Drug: Monotherapy Etoricoxib
One tablet aog 90 mg a day, for 14 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in pain during active movement of the affected joint (VAS 100 mm) at Days 3, 7, 10, and 14 vs baseline, by treatment group.
Time Frame: Baseline and Days 3, 7, 10, and 14
Pain intensity during active movement will be assessed using a 100-mm Visual Analog Scale (VAS) to determine whether the fixed-dose combination etoricoxib/betamethasone produces a greater reduction in pain compared with etoricoxib alone. Assessments will be obtained at baseline and at follow-up timepoints.
Baseline and Days 3, 7, 10, and 14
Number of participants with adverse events, and comparison of adverse event frequency and intensity, by treatment group.
Time Frame: Up to 14 days
Safety will be assessed by comparing adverse events occurring during the study between treatment groups. Adverse events will be summarized using frequencies and percentages and classified according to seriousness/gravity, severity, and causality.
Up to 14 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Baseline sociodemographic, anthropometric, biochemical, and clinical characteristics, by treatment group.
Time Frame: Baseline
Descriptive summary of participant characteristics at baseline by randomized group.
Baseline
Daily change in maximum pain during active movement of the affected joint (VAS 100 mm) over 14 days vs baseline, by treatment group.
Time Frame: Daily through Day 14
Patients will record daily VAS scores to estimate the magnitude of change from baseline in maximum pain during active movement throughout treatment.
Daily through Day 14
Daily change in maximum pain at rest of the affected joint (VAS 100 mm) over 14 days vs baseline, by treatment group.
Time Frame: Daily through Day 14
Patients will record daily VAS scores at rest to estimate the magnitude of change from baseline throughout treatment
Daily through Day 14
Clinical improvement using the Clinical Global Impression (CGI) scale at Days 7 and 14 vs baseline, by treatment group.
Time Frame: Baseline, Day 7, and Day 14
Clinical improvement will be evaluated using CGI (severity/improvement categories) at follow-up and compared with baseline by treatment group.
Baseline, Day 7, and Day 14
Change in Patient Global Assessment of current condition at Days 7 and 14 vs baseline, by treatment group.
Time Frame: Baseline, Day 7, and Day 14
The Patient Global Assessment will be recorded and changes from baseline will be described by treatment group.
Baseline, Day 7, and Day 14
Proportion of patients by category on the Patient Global Assessment at Days 7 and 14 vs baseline, by treatment group.
Time Frame: Baseline, Day 7, and Day 14
Changes in the proportion of patients reporting feeling very well, well, fair, poor, or very poor will be summarized by group.
Baseline, Day 7, and Day 14
Change in Investigator Global Assessment at Days 7 and 14 vs baseline, by treatment group.
Time Frame: Baseline, Day 7, and Day 14
The Investigator Global Assessment will be recorded and changes from baseline will be described by treatment group.
Baseline, Day 7, and Day 14
Proportion of patients by category on the Investigator Global Assessment at Days 7 and 14 vs baseline, by treatment group.
Time Frame: Baseline, Day 7, and Day 14
Changes in the proportion of participants classified as very well, well, fair, poor, or very poor by the investigator will be summarized by group.
Baseline, Day 7, and Day 14

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Laboratorios Silanes S.A. de C.V.

Investigators

  • Principal Investigator: Marco Antonio Cordova Martinez, MD, Unidad de Medicina Especializada SMA SC
  • Principal Investigator: Pedro Abraham Garza Alvarez, MD, IECSI Clinical Research
  • Principal Investigator: Juan Luis Torres Mendez, MD, Clinical Research Institute S.C.
  • Principal Investigator: Yazmin Adriana Guerra Lopez, MD, Centro de Investigación Clínica de México S. de R.L. de C.V

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 14, 2025

Primary Completion (Actual)

August 20, 2025

Study Completion (Actual)

November 19, 2025

Study Registration Dates

First Submitted

December 28, 2025

First Submitted That Met QC Criteria

December 28, 2025

First Posted (Actual)

January 8, 2026

Study Record Updates

Last Update Posted (Actual)

January 8, 2026

Last Update Submitted That Met QC Criteria

December 28, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SIL-30953-III-24(1)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bursitis

Clinical Trials on Fixed Dose Etoricoxib + Betamethasone

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe